CClinicalTrials.gg
Not yet recruitingNCT07789353Updated Aug 31, 2026

Impact of Pharmacist-led Care Navigation Mediated by Digital Health Tools on Hospital Readmissions

An interventional study of Pharmacist-led teleconsultations in Ambulatory Care Sensitive Conditions, sponsored by Hospital de Clinicas de Porto Alegre. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
3,220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hospitalizations for Primary Care-Sensitive Conditions (PCSCs) are potentially avoidable hospital admissions that may be prevented when Primary Health Care provides effective and timely care through prevention, early diagnosis, appropriate management of chronic conditions, and control of acute episodes.

This study proposes an open-label, pragmatic, cluster-randomized clinical trial to evaluate the effectiveness of continuous telecare, supported by digital health tools, in the post-discharge follow-up of patients hospitalized for PCSCs.

The main outcome will be the occurrence of non-elective hospital readmissions and urgent or emergency care visits within 180 days after discharge, compared with usual care.

The intervention will include pharmacist-led teleconsultations, a communication channel through a messaging app, and the development of an individualized care plan. Participants in the control group will receive the usual care provided by the healthcare network.

02

Conditions studied

  • Ambulatory Care Sensitive Conditions

Keywords

  • Transitional Care
  • Ambulatory Care Sensitive Conditions
  • Remote Patient Monitoring
  • Patient Readmission
  • Patient Discharge
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals aged 18 years or older;
  • Residing in the municipality of Porto Alegre;
  • Hospitalized at Hospital de Clínicas de Porto Alegre for selected Primary Care-Sensitive Conditions (PCSCs): respiratory diseases (such as asthma, chronic obstructive pulmonary disease, and tuberculosis), cardiovascular diseases (such as arterial hypertension, angina, and heart failure), cerebrovascular diseases (such as stroke), and metabolic diseases (such as diabetes mellitus).

Exclusion criteria

Exclusion Criteria:

  • Individuals who are unable to be contacted by telephone;
  • Individuals with language or cognitive barriers that cannot be overcome with the assistance of a caregiver or legal representative;
  • Individuals participating in another clinical trial that conflicts with the present study.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,220 participants (estimated)

Study arms

  • Active comparator
    Pharmacist-led teleconsultations

    Continuous pharmacist-led care program supported by digital health tools, which will include: three pharmacist teleconsultations, with the first consultation within 15 days after hospital discharge, the second within 30 days, and the third within 90 days; an open communication channel through a messaging app; an individualized care plan; and referrals to Primary Health Care professionals, when necessary.

    Behavioral: Pharmacist-led teleconsultations

  • No intervention
    Usual care

    Usual care provided by the hospital and Primary Health Care services, without implementation of the structured pharmacist-led care program supported by digital health tools.

Interventions

  • BehavioralPharmacist-led teleconsultations

    Continuous pharmacist-led care program supported by digital health tools, which will include: three pharmacist teleconsultations, with the first consultation within 15 days after hospital discharge, the second within 30 days, and the third within 90 days; an open communication channel through a messaging app; an individualized care plan; and referrals to other Primary Health Care professionals, when necessary.

    Also known as: Remote Consultation, Remote Patient Monitoring, Community Pharmacy Services, Pharmaceutical Services, Online, Pharmaceutical Services, Medication Therapy Management

05

What researchers measure

Primary outcomes

  1. Occurrence of non-elective hospital readmissions and visits to urgent and emergency care services within 180 days after hospital discharge

    Occurrence of non-elective hospital readmissions and visits to urgent and emergency care services within 180 days after hospital discharge, assessed through patient/caregiver reports during follow-up visits and electronic medical records.

    Time frame: From enrollment until 180 days after hospital discharge

Secondary outcomes

  1. Proportion of participants who died within 180 days after hospital discharge

    Proportion of participants who died within 180 days after hospital discharge, assessed through caregiver reports and medical records.

    Time frame: From enrollment until 180 days after hospital discharge

  2. Proportion of participants who fully or predominantly completed the actions outlined in the individualized care plan

    Proportion of participants who fully or predominantly completed the actions outlined in the individualized care plan, as documented in pharmacist teleconsultations and medical records. An individualized care plan will be developed for each participant based on the Clinical Protocols and Therapeutic Guidelines of the Brazilian Ministry of Health and will include agreed-upon actions. Throughout the follow-up period, completion of the planned actions will be documented. Participants will be considered adherent to the care plan if there is documentation that they completed all planned actions or at least 75% of them within the defined period.

    Time frame: From enrollment until 180 days after hospital discharge

  3. Satisfaction with continuous pharmacist-led care

    Satisfaction with continuous pharmacist-led care will be assessed using the Net Promoter Score (NPS), based on the standard question: "On a scale from 0 to 10, how likely are you to recommend pharmacist-led telecare to a friend or family member?". Respondents will be classified as promoters (score 9-10), passives (score 7-8), or detractors (score 0-6). The NPS will be calculated as the difference between the percentage of promoters and the percentage of detractors, resulting in a score ranging from -100 to +100 (NPS = % Promoters - % Detractors).

    Time frame: From enrollment until 180 days after hospital discharge

06

Study locations

1 site
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Brazil
07

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to external researchers. The study protocol approved by the institutional Research Ethics Committee does not include the sharing of individual participant data with researchers outside the primary research team. Individual participant data collected in this study include sensitive personal health information and will be used exclusively for the purposes specified in the approved study protocol. Study findings will be disseminated through scientific publications and other scientific communications using aggregate data.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07789353
Lead sponsor
Hospital de Clinicas de Porto Alegre
Collaborators
Institute of Artificial Intelligence in Health
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Aug 31, 2026

Study contacts

Bianca V Bianchini, PhD
Contact
bianca@noharm.ai
+55 51 31914125
Diego Gnatta, PhD
study chair · Federal University of Rio Grande do Sul

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion